Detecting copy number variations (CNVs) and alterations (CNAs) in the BRCA1 and BRCA2 genes is essential for testing patients for targeted therapy applicability. However, the available bioinformatics tools were initially designed for identifying CNVs/CNAs in whole-genome or -exome (WES) NGS data or targeted NGS data without adaptation to the BRCA1/2 genes. Most of these tools were tested on sample cohorts of limited size, with their use restricted to specific library preparation kits or sequencing platforms. We developed BRACNAC, a new tool for detecting CNVs and CNAs in the BRCA1 and BRCA2 genes in NGS data of different origin. The underlying mechanism of this tool involves various coverage normalization steps complemented by CNV probability evaluation. We estimated the sensitivity and specificity of our tool to be 100% and 94%, respectively, with an area under the curve (AUC) of 94%. The estimation was performed using the NGS data obtained from 213 ovarian and prostate cancer samples tested with in-house and commercially available library preparation kits and additionally using multiplex ligation-dependent probe amplification (MLPA) (12 CNV-positive samples). Using freely available WES and targeted NGS data from other research groups, we demonstrated that BRACNAC could also be used for these two types of data, with an AUC of up to 99.9%. In addition, we determined the limitations of the tool in terms of the minimum number of samples per NGS run (≥20 samples) and the minimum expected percentage of CNV-negative samples (≥80%). We expect that our findings will improve the efficacy of BRCA1/2 diagnostics. BRACNAC is freely available at the GitHub server.
11 June 2025 in Traumatology and Orthopedics of Russia
Background. Staphylococcus aureus is one of the most common pathogens causing periprosthetic joint infection (PJI). Despite the high genetic diversity of S. aureus strains, determining phylogenetic relationships and, consequently, the source of infection is a challenging task that can only be addressed through detailed comparison of the genomes of the obtained isolates. The aim of the study was to assess the feasibility of differentiating the cases of nosocomial periprosthetic joint infections, using whole-genome sequencing to identify genetic and phenotypic differences between isolates with the prospect of the application of evidence-based treatment strategies. Methods. Genomes of 20 S. aureus isolates from 13 patients with PJI were sequenced. Standard microbiological tests and in silico analysis of genomes using ResFinder, KmerFinder, spaTyper, and SCCmecFinder programs were employed. Results. Phylogenetic analysis was performed using core genome reconstruction and identified potential cases of nosocomial infections, as well as cases of recurrent infections. The relatedness of isolates collected between 2012 and 2019 was demonstrated, along with the evolution of their genomes, including the acquisition and loss of antibiotic resistance genes. In one case of recurrent infection, the loss of several genes was observed over a remission period of approximately 5 years. Comparison of phenotypic testing results using the disk diffusion method and resistance predictions based on genome analysis revealed discrepancies for three isolates containing the aac(6’)-aph(2’’) gene, which were resistant to tobramycin and gentamicin but susceptible to amikacin. Based on the treatment outcomes of several recurrent PJI cases, it was hypothesized that radical treatment might be more effective in cases of infections caused by multidrug-resistant nosocomial strains. Conclusions. Whole-genome sequencing enables the identification of phylogenetically related isolates, with shared genetic and phenotypic properties confirming their relatedness. Against the backdrop of high-dose antibiotic therapy, S. aureus genomes accumulate changes that, through molecular genetic testing, may help to justify the choice of radical treatment strategy for periprosthetic joint infection, such as prosthesis removal.